CTOs on the Move

Dragon Pharmaceuticals

www.dragonpharmaceuticals.com

 
Dragon Pharmaceuticals Inc. (OTC-BB: Drug) is an international biotech company headquartered in Vancouver, Canada, with production and R&D facilities in Nanjing, China and 160 employees worldwide. The Company develops and commercializes human proteins for therapeutic use. Using superior and proprietary DNA vector technology, Dragon is able to produce high yields of quality protein drugs at low costs and high margins. Dragon is one of the world`s largest producers of Epoetin Alfa, or EPO, a therapeutic protein used to treat anemia related to kidney failure, chemotherapy, and surgery. Dragon`s EPO is approved and being marketed for use in chronic renal failure in ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Apotex

Apotex is the largest Canadian owned pharmaceutical company, and the largest producer of generic medicines in the country. Founded in 1974, Apotex has steadily grown to employ over 10,000 people around the world, focused on research, development, manufacturing and distribution.

Clinical DataFax Systems

Clinical DataFax Systems, Inc. is a Hamilton, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Team Wellness Center

Team Mental Health Services is dedicated to enhancing the well-being of individuals by providing an array of comprehensive behavioral and physical services in an environment that promotes quality of life, continuous improvement and social awareness. ...

PBN Pharma

PBN Pharma is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncology Pharma

Oncology Pharma, Inc. is a pioneering oncology company dedicated to licensing, developing, manufacturing and commercializing therapeutics. The company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the field of oncology, therapeutics and leadership to identify, negotiate and amalgamate “best in class” research, technologies, therapeutics and delivery mechanisms that are synergistic and collaborative. The goal is to create value, reduce costs and increase the speed of regulatory approval and commercialization of effective and safer cancer drugs.